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 The quality in the pharmaceutical industry has become a very important topic. Pharmaceutical 
industry has been emerging rapidly for the last decade by focusing on product Quality, Safety, 
and Efficacy. The guidelines of ICH from Q8 to Q11 have discussed QbD implementation in 
pharmaceutical product formulation development. ICH Q11 is a clear discussion about QbD 
approach for API (Active Pharmaceutical Ingredient) synthesis with examples. 
Pharmaceutical firms increased the number of product development by using different 
scientific tools such as QbD (Quality by Design) and PAT (Process Analytical Technology). 
The main key tools of AQbD are identification of ATP (Analytical Target Profile), CQA 
(Critical Quality Attributes) with risk assessment, Method Optimization and Development 
with DoE, MODR (method operable design region), Control Strategy, AQbD Method 
Validation, and Continuous Method Monitoring (CMM), TQM (Total Quality Management), 
DOE (Design of Experiments). Implementation of AQbD simultaneously in analytical 
development will improve the ability of production of high quality products which will 
minimize the risks during every step of manufacturing and analysis of products. 
Please cite this article in press as P. Abhinandana et al. Implementing of Analytical Quality by Design for High Quality 
Pharmaceutical Products. Indo American Journal of Pharmaceutical Research.2017:7(07). 
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INTRODUCTION [1-3] 
Nowadays analytical quality by design became a big concern for pharmaceutical industries as the quality should incorporate 
and tested in each and every step of production of pharmaceutical production. All the regulatory authorities are particular about 
implementing ICH Q8 to Q11 which are the guidelines regarding to Quality. So that all pharmaceutical industries has been focusing 
on product Quality, Safety and Efficacy. The product quality has been increasing by implementing QBD (Quality by design) and PAT 
(Process analytical techniques). 
 
WHAT IS ANALYTICAL QUALITY BY DESIGN? [4-9] 
Quality by design (QbD) can be defined as “A systematic approach to development that begins with predefined objectives 
and emphasizes product and process understanding and process control, based on sound science and quality risk management” as per 
ICH.[4]  
AQbD is also an element which will help in maintaining product quality. By incorporating some tools related to AQbD the 
robustness of a pharmaceutical product can be increased. Those tools includes ATP (Analytical Target Profile), CQA, Risk 
Assessment, Method Optimization and Development with DoE, MODR (method operable design region), Control Strategy and Risk 
Assessment. Although there is no specific discussion about this AQbD in ICH like QbD (Q11) for the better production of high quality 
product the scientific approach for the AQbD has become big source. Both QbD and AQbD can be applied to the product in similar 
time.FIG [5-9]. 
 
 
 
Figure.1.AQbD TOOLS. 
 
THE MAJOR DIFFERENCES BETWEEN QbD AND AQbD:[10-13] 
It is like traditional and scientific approach. For traditional approach there is no use of statistical calculations and risk 
assessments where AQbD main concept is applying of statistical calculations and risk assessments, control strategy and continuous 
method monitoring while preparation of pharmaceutical product and as well as development of analytical method for that product. 
[10-11]There is lot of benefits applying this AQbD pharmaceutically which hopefully leads to building of more quality into a 
product.FIG.2[12-13] 
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Figure.2.Tools for both synthetic and analytical development. 
 
ANALYTICAL TARGET PROFILE (ATP):[14-17] 
ATP is like QTTP in QbD. This will include with method selection for a particular product and all the risk assessment along 
with method. [14-16] 
The major things that will come under ATP are 
i) Type of product (whether is API or Impurity) 
ii) Type of technique selection (by HPLC, GC, HPTLC or other techniques for its estimation. 
iii) Method selection and its requirements (assay and impurity identification) 
iv) Requirements for the procedure (solvents, solutions, columns). 
 
ANALYTICAL APPROACH IN R&D DEVELOPMEMNT 
 
 
 
FIR.3. AQbD Approach for an analytical method development. 
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ATP also involves in the selection of an analytical technique and the parameters of method requirements. 
i) By FTIR or spectrophotometer 
ii) HPLC or spectroscopy 
iii) Assay or impurity profiling by HPLC with different detectors 
iv) Impurity profiling by GC 
v) Selection of method requirements like solvents needed and columns for the particular method, flow rate, wavelength, and mobile 
phase combinations which will comes under CQA.  
 
CRITICAL QUALITY ATTRIBUTES (CQA): 
Critical quality attribute is the parameter which involves in the selection of method requirements which includes [17] 
For HPLC  
(i) What is the mobile phase & its organic combinational ratios 
(ii) What is flow rate and wavelength? 
(iii) Diluents and drug concentration 
(iv) Selection of column which suits for the drug and mobile phase  
 
For HPTLC and TLC 
(i) pH of the mobile phase 
(ii) polarity  
(iii) Type of TLC plate 
(iv) Injection volume and its concentration 
(v) Development of TLC plate 
(vi) Color of the Reagents  
 
For GC 
(i) Type of carrier gas 
(ii) Detector and its wavelength 
(iii) Diluents and sample concentrations 
(iv) Pressure of the system 
All these parameters can be planned in detailed when its come to design of experiments. 
 
INITIAL RISK ASSESSMENT [18] 
Initial risk assessments come under CQA and it involves in the risk assessment and method monitoring of a particular method 
at early stages of process beginning.  The main goal of AQbD is to develop a method which will lead to production of high quality 
product. This will happen only when the production or analysis of a product is monitored in each and every step and assessment of 
risks and plan of work which will overcome those risks. 
So that risk assessment from early stages of starting material to final product is an important task. 
 
 
DESIGN OF EXPERIMENTS (DOE) - [INVOLVES IN METHOD OPTIMIZATION AND METHOD DEVELOPMENT] 
After the assessment of risks there is a need of design of experiments depending upon the priority of the method 
requirements. For an analytical method is there is necessity of proper planning of the work staring with mobile phase and ending 
calculation of impuritites or assay values.FIG.4 [19] 
By designing in this way it is predictable what will be the result is and there is a lot of possibilities to increase the successful 
estimation of a product and minimization of errors. It also gives a benefit of decreasing of the repeated steps and statistical 
calculations are very important for evaluation of critical method variables. There is possibility to obtain good robustness within 
methods by DOE.[19] 
 
METHOD OPERABLE DESIGN REGION (MODR)[20] 
MODR is the tool which will provide multidimensional combinations and interactions of method parameters leading to meet 
measurement requirements. It will target to develop a method which is less risk to the method performance. 
 
CONTROL STRATEGY AND RISK ASSESSMENT[21-24 ] 
A control strategy is designed to ensure that a product of required quality will be produced consistently. For a given product 
various approaches for control strategy can be possible like in-process testing and end product testing. 
Understanding sources of variability and their impact on downstream processes or processing, in-process materials, and drug 
product quality can provide an opportunity to shift controls upstream and minimize the need for testing of end product. 
The risk assessment activities indicate that the overall understanding of method performance can be improved, and the risk to 
obtaining reliable data is high and difficult to manage, a more appropriate method may be needed.FIG.5. 
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Understanding sources of variability and their impact on downstream processes or processing, in-process materials, and drug 
product quality can provide an opportunity to shift controls upstream and minimize the need for testing of end product. 
The risk assessment activities indicate that the overall understanding of method performance can be improved, and the risk to 
obtaining reliable data is high and difficult to manage, a more appropriate method may be needed.FIG.5. If the risks are measured low 
then the control strategy can be explained as defined system suitability and method can deliver the desirable method attributes. The 
appropriate system suitability is the controllable element which will be needed in ensuring of performance of selected method. 
 
     Equipmenmt                        Analyte                           Initialize 
 
                  Injector                              Solubility                             weighing 
                         Detector,                             Stability                          Sonication/centrifuge 
 
 
 
 
                   Buffer pH                            Gradient                           Purity 
             Organic solvents                     isocratic                             Repeatability 
 
Material                                Method/Elution            Report 
               FIG.5.Fish bone risk assessment for analytical method 
 
 
 
AQbD METHOD VALIDATION:[ 25-26 ] 
Analytical quality by design Validation is required for each batch of API or final finished product for the confirmation of its 
quality. It will use both the knowledge from MODR and DOE for all kind of products with revalidation capability. AQbD is the tool 
which will reveal the product quality without any compromises by following ICH guidelines and by utilizing of control strategy and 
continuous improvement. 
 
CONTINOUS METHOD MONITORING AND CONTINUAL IMPROVEMENT: [27-30 ] 
For AQbD, CMM is the final step as it includes continual improvement of method or process throughout the product lifecycle 
by control strategy and risk assessments. Knowledge of design of experiments and MODR, ATP CAQ and control strategy are the 
tools which can monitor the product quality throughout the process and minimizing the errors in process is the main theme of these 
tools.FIG.6. 
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FIG.6.Product Quality monitoring. 
 
ADVANTAGES:[31-32] 
AQbD can be applied to biopharmaceutical, clinical and genetically. To deliver a product at its maximum rate of purity, 
potency and biological availability undoubtedly AQbD is a big hope for the pharmaceutical industries. As per ICH guidelines Q8 
(Quality of pharmaceutical product) a drug product should be manufactured with proper planning and monitoring and should contain 
high quality at its maximum rate of availability biologically. By applying risk assessments and control strategy with continuous 
method monitoring as the tools of AQbD it is possible to minimize the errors in production and it will control the method failures also. 
 
CONCLUSION 
As the product quality is the main theme for the pharmaceutical industries it is preferable to apply Analytical Quality by 
design as the tools of this AQbD like ATP, CQA, Method Optimization and Development with DOE, MODR, and Control Strategy 
with Risk Assessment, Method validation and Continuous Method Monitoring (CMM), and continuous improvement will give the 
best results than traditional methods. Risk assessment is the main tool which is helpful to minimize the timelines and fewer chances of 
method failures. 
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